18 August 2021 - Early treatment study
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
et al., NEJM, doi:10.1056/NEJMoa2103784 (Peer Reviewed)
RCT 511 emergency department patients, 257 assigned to convalescent plasma, showing no significant difference in outcomes.
|
risk of death, 396.0% higher, RR 4.96, p = 0.22, treatment 5 of 250 (2.0%), control 1 of 248 (0.4%).
|
|
risk of hospitalization, 10.0% lower, RR 0.90, p = 0.59, treatment 51 of 257 (19.8%), control 56 of 254 (22.0%), NNT 45.
|
|
risk of progression, 6.0% lower, RR 0.94, p = 0.70, treatment 77 of 257 (30.0%), control 81 of 254 (31.9%), NNT 52.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Korley et al., 8/18/2021, Randomized Controlled Trial, USA, North America, peer-reviewed, 28 authors, average treatment delay 3.7 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.